Use of a Daratumumab-Specific Immunofixation Assay to Assess Possible Immunotherapy Interference at a Major Cancer Center: Our Experience and Recommendations.

Kirchhoff, Daniel C; Murata, Kazunori; Thoren, Katie L

Kirchhoff, Daniel C; Murata, Kazunori; Thoren, Katie L.

Afiliación

Kirchhoff DC; Clinical Chemistry Service, Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Murata K; Clinical Chemistry Service, Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Thoren KL; Clinical Chemistry Service, Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

J Appl Lab Med ; 6(6): 1476-1483, 2021 11 01.

Article en En | MEDLINE | ID: mdl-34293131

Asunto(s)

Anticuerpos Monoclonales; Neoplasias; Humanos; Inmunoelectroforesis; Inmunoterapia; Neoplasias/tratamiento farmacológico; Estudios Retrospectivos

Palabras clave

Hydrashift; daratumumab; false positive; guidelines; interference; multiple myeloma

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales / Neoplasias Tipo de estudio: Guideline / Observational_studies Límite: Humans Idioma: En Revista: J Appl Lab Med Año: 2021 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google